Prostate cancer screening
- Shandra S. Wilson
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Prostate cancer is the leading noncutaneous cancer in men of the Western world. Because of its prevalence and ability to cause morbidity and mortality, prostate cancer screening continues to be an important area of focus in health care. This article covers the sensitivity and specificity of prostate-specific antigen and current techniques used to improve the test’s validity, the importance of detecting clinically important cancers with screening, as well as the downward stage migration, decreased disease-specific mortality, and decreased metastases rate seen in patients screened and treated for prostate cancer.
- Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003. CA Cancer J Clin 2003;53:5–26. CrossRef
- Brawer MK. Prostate-specific antigen: current status. CA Cancer Journal Clinics 1999;49(5):264–281.
- Hakama M, Stenman U, Aromaa A, et al. Validity of the prostate specific antigen tests for prostate cancer screening: follow-up study with a bank of 21,000 sera in Finland. J Urol 2001;166(6):2189–2192. CrossRef
- Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995;273(4):289–294. CrossRef
- Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6.630 men. J Urol 1994;151:1283–1290.
- Punglia RS, D’Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. NEJM 2003;394(4):225–242.
- Liu S, Lee IM, Linson P, et al. A prospective study of physical activity and risk of prostate cancer in US physicians. Int J Epidem 2000; 29(1):29–35. CrossRef
- Thompson IM, Goodman PH, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. NEJM 2003; 349(3):211–220. CrossRef
- Stamey TA, Johnstone IM, McNeal JE, et al. Pre-operative serum prostate-specific antigen levels between 2 and 22 ng/mL correlate poorly with post-radical prost atectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/mL. J Urol 2002;167(1):103–111. CrossRef
- Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate-specific antigen values. J Urol 1994;151:1571–1574.
- Hammerer PG, McNeal JE, Stame TA. Correlation between serum prostate-specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 1995;153(1):111–114. CrossRef
- Okegawa T, Kino M, Ohata M, et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1–10ng/mL. Int J Urol 2003;10(4):201–206. CrossRef
- Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170(2 part 1):442–446. CrossRef
- Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003;62 (Suppl. 1):19–35. CrossRef
- Merrill RM, Potosky AL, Feuer EJ. Changing trends in the US prostate cancer incidence rates. J Natl CA Inst 1996;88:1683–1685. CrossRef
- Breslow N, Chang CW, Dhom G, et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J CA 1977;20:680. CrossRef
- Epstien J, Walsh P, Carmichael M, et al. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 1994;271:368–374. CrossRef
- Thompson I, Presti J. Recent advances in the management of prostate cancer. Faculty Update 2003.
- McLaughlin AP, Saltzstein SL, McCullough DL, et al. Prostatic carcinoma: Incidence and location of unsuspected lymphatic metastases. J Urol 1976;115:89–94.
- Thompson IM, Ernst JJ, Gangai MP, et al. Adenocarcinoma of the prostate: Results of routine urological screening. J Urol 1984: 132:690–692.
- Gohagan JK, Prorok PC, Hayes RB, et al. SEER Cancer Statistics Reviewed 1973–1999. Bethesda MD: National Cancer Institute, 2002.
- Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate specific antigen. JAMA 1996; 276(16):1309–1315. CrossRef
- Jhaveri FM, Klien EA, Kupelian PA, et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Onc 1999;17(10):3167–3172.
- Gustafsson O, Norming U, Almgard LE, et al. Diagonstic methods in the detection of prostate cancer. A study of randomly selected population of 3,000 men. J Urol 1992;148:1827.
- Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy: the national medicare experience 1988–1990. JAMA 1993;269:2663.
- Catalona W, Antenor JV, Roehl KA. Screening for prostate cancer in high risk populations. Journal of Urology 2002;168(5):1980–1984. CrossRef
- Thomson IM, Optenberg SA. An overview cost-utility analysis of prostate cancer screening. Oncology (Huntington) 1995;9 (Suppl. II):141–145.
- Ross KS, Carter HB, Pearson JD, et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000;248(11):1399–1405. CrossRef
- Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 1997;349:906–910. CrossRef
- Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38(2):83–91. CrossRef
- Meyer F, Moore L, Bairati I, et al. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999;161:1889. CrossRef
- Oliver, SE, May MT, Gunnell, D. International trends in prostate-cancer mortality in the “PSA era”. Int J CA. 2001;92:893–898. CrossRef
- Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, an update on incidence trends in Olmsted County, Minnesota. J Urol 1999;161:529–533. CrossRef
- Gronberg H, Damber J, Jonsson H, et al. Patint age as a prognostic factor in prostate cancer. J Urol 1994;152:892–895.
- Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence, and mortality. Part I: International comparisons. Br J Urol 2002;90(2):162–173.
- Crocetti E, Ciatto S, Zappa M. Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy. J Nat CA Inst. 2001;93:876–877. CrossRef
- Etzioni R, Legler J, Feuer E, et al. Cancer surveillance series: intepreting trends in prostate cancer—part III: qualifying the link between population porstate-specific antigen testing and recent declines in prostate cancer mortality. J Nat CA Inst 1999;91:1033–1039. CrossRef
- Oliver SE, Gunell D, Donovan JL. Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet. 2000;355:1788–1789. CrossRef
- Perron L, Morre L, Bairate I, et al. PSA screening and prostate cancer mortality. Can Med Assoc J 2002;166(5):586–591.
- Makinen T, Tammela TLJ, Hakama M, et al. Tumor characteristics in a population-based prostate cancer screening trial with prostate specific antigen. Clin CA Rsch 2003;9:2435.
- Coley, CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer: Incidence, prior probability, and effectiveness of tests. Ann Int Med 1997;126:394–406.
- Holmberg L, Bill-Axelson A, Helgessen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. New England Journal of Medicine 2002; 347:781–789. CrossRef
- Auvinen A, Rietbergen JB, Denis LJ, et al. Prospective evaluation plan for randomized trial of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screening 1996;3:97–104.
- Gohagan JK, Prorok PC, Hayes RB, et al. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history organization, and status. Contr Clin Trials 2000;21 (suppl 6): 251S-252S. CrossRef
- Borre M, Nerstrom B, Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer. 1997;80(5):917–928. CrossRef
- Prostate cancer screening
Volume 31, Issue 2 , pp 119-123
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Author Affiliations
- 1. University of Colorado Anschutz Cancer Center, 1665 North Ursula, MS 710, 800 10, Aurora, CO